Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub was pleased to speak with Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Does prior use of checkpoint inhibitors impact allogeneic stem cell transplantation outcomes for patients with Hodgkin lymphoma?

Perales begins by discussing the new therapies that have become available in the past decade to treat Hodgkin lymphoma, such as rituximab and checkpoint inhibitors. This is followed by a summary of the joint study between the Center for International Blood and Marrow Transplant Research (CIBMTR) and EBMT, which aimed to investigate if receiving a checkpoint inhibitor prior to allogeneic transplant impacted progression-free and overall survival in patients with Hodgkin lymphoma. Perales finishes by discussing the importance of having a curative approach available.